Catechol-O-methyltransferase and 3,4-(±)-methylenedioxymethamphetamine toxicity

Toxicological Sciences

Volumn 139, Issue 1, 2014, Pages 162-173

  Herndon, Joseph M ^a   Cholanians, Aram B ^a   Lizarraga, Lucina E ^a   Lau, Serrine S ^a   Monks, Terrence J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

3,4 ( ) methylenedioxymethamphetamine; Catechol O methyltransferase; Hyperthermia

Indexed keywords

2' FLUORO 3,4 DIHYDROXY 5 NITROBENZOPHENONE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CATECHOL METHYLTRANSFERASE; NORADRENALIN; SEROTONIN; 3,4 METHYLENEDIOXYAMPHETAMINE; BENZOPHENONE DERIVATIVE; PRIMER DNA; RO 41-0960;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORE TEMPERATURE; CORPUS STRIATUM; CYTOSOLIC FRACTION; DISEASE EXACERBATION; ENZYME INHIBITION; FEMALE; FRONTAL CORTEX; GENETIC MODEL; GENOTYPE; HIPPOCAMPUS; HYPERTHERMIA; LIMIT OF DETECTION; MALE; METABOLITE; MICROSOME; NEUROTOXICITY; NONHUMAN; NORADRENALIN BLOOD LEVEL; RAT; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; ELECTROCHEMICAL ANALYSIS; ENZYMOLOGY; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; SPRAGUE DAWLEY RAT; TOXICITY;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; BASE SEQUENCE; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA PRIMERS; ELECTROCHEMICAL TECHNIQUES; FEMALE; FEVER; LIVER; MICE; MICE, INBRED C57BL; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84899837459     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu035     Document Type: Article

References (49)

1. Antolino-Lobo, I., Meulenbelt, J., Nijmeijer, S. M., Scherpenisse, P., van den Berg, M., and van Duursen, M. B. (2010). Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity. Drug Metab. Dispos. 38, 1105-1112.
2. Bai, F., Jones, D. C., Lau, S. S., and Monks, T. J. (2001). Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)- methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem. Res. Toxicol. 14, 863-870.
3. Bai, F., Lau, S. S., and Monks, T. J. (1999). Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: Possible role inmethylenedioxyamphetamine-mediated neurotoxicity. Chem. Res. Toxicol. 12, 1150-1157.
4. Battaglia, G., Yeh, S. Y., and De Souza, E. B. (1988). MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29, 269-274.
5. Benamar, K., Geller, E. B., and Adler, M. W. (2008). A new brain area affected by 3,4-methylenedioxymethamphetamine: A microdialysisbiotelemetry study. Eur. J. Pharmacol. 596, 84-88.
6. Bexis, S., and Docherty, J. R. (2009). Role of alpha 1- and beta 3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse. Br. J. Pharmacol. 158, 259-266.
7. Cadet, J. L., Ladenheim, B., Baum, I., Carlson, E., and Epstein, C. (1994). CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res. 655, 259-262.
8. Capela, J. P., Carmo, H., Remiao, F., Bastos, M. L., Meisel, A., and Carvalho, F. (2009).Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: An overview. Mol. Neurobiol. 39, 210-271.
9. Capela, J. P., Macedo, C., Branco, P. S., Ferreira, L. M., Lobo, A. M., Fernandes, E., Remiao, F., Bastos, M. L., Dirnagl, U., Meisel, A., et al. (2007). Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146, 1743-1757.
10. Carmo, H., Brulport, M., Hermes, M., Oesch, F., Silva, R., Ferreira, L. M., Branco, P. S., Boer, D., Remiao, F., Carvalho, F., et al. (2006). Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity. Pharmacogenet. Genomics 16, 789-799.
11. Chen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T.M., Herman, M.M., Apud, J., et al. (2004). Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75, 807-821.
12. Colado, M. I., O'Shea, E., Granados, R., Esteban, B., Martin, A. B., and Green, A. R. (1999). Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4- methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. Br. J. Pharmacol. 126, 911-924.
13. Colado, M. I., Williams, J. L., and Green, A. R. (1995). The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4- methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 115, 1281- 1289.
14. Cuyas, E., Verdejo-Garcia, A., Fagundo, A. B., Khymenets, O., Rodriguez, J., Cuenca, A., de Sola Llopis, S., Langohr, K., Pena-Casanova, J., Torrens, M., et al. (2011). The influence of genetic and environmental factors among MDMA users in cognitive performance. PLoS One 6, e27206.
15. Dacks, P. A., and Rance, N. E. (2010). Effects of estradiol on the thermoneutral zone and core temperature in ovariectomized rats. Endocrinology 151, 1187- 1193.
16. de la Torre, R., and Farre, M. (2004). Neurotoxicity of MDMA (ecstasy): The limitations of scaling from animals to humans. Trends Pharmacol. Sci. 25, 505-508.
17. de la Torre, R., Farre, M., Mathuna, B. O., Roset, P. N., Pizarro, N., Segura, M., Torrens, M., Ortuno, J., Pujadas, M., and Cami, J. (2005). MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur. J. Clin. Pharmacol. 61, 551-554.
18. de la Torre, R., Farre, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., and Cami, J. (2004). Human pharmacology of MDMA: Pharmacokinetics, metabolism, and disposition. Ther. Drug Monit 26, 137-144.
19. Eisenhofer, G., Aneman, A., Hooper, D., Rundqvist, B., and Friberg, P. (1996). Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. J. Neurochem. 66, 1565-1573.
20. Erives, G. V., Lau, S. S., and Monks, T. J. (2008). Accumulation of neurotoxic thioether metabolites of 3,4-(+/-)-methylenedioxymethamphetamine in rat brain. J. Pharmacol. Exp. Ther. 324, 284-291.
21. Escobedo, I., O'Shea, E., Orio, L., Sanchez, V., Segura, M., de la Torre, R., Farre, M., Green, A. R., and Colado, M. I. (2005). A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br. J. Pharmacol. 144, 231-241.
22. Esteban, B., O'Shea, E., Camarero, J., Sanchez, V., Green, A. R., and Colado, M. I. (2001). 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl.) 154, 251-260.
23. Fisher, C. D., Lickteig, A. J., Augustine, L. M., Oude Elferink, R. P., Besselsen, D. G., Erickson, R. P., and Cherrington, N. J. (2009). Experimental nonalcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol. 613, 119-127.
24. Fonsart, J., Menet, M. C., Decleves, X., Galons, H., Crete, D., Debray, M., Scherrmann, J. M., and Noble, F. (2008). Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4- methylenedioxymethamphetamine (MDMA, ecstasy). Toxicol. Appl. Pharmacol. 230, 117-125.
25. Goni-Allo, B., B, O. M., Segura, M., Puerta, E., Lasheras, B., de la Torre, R., and Aguirre, N. (2008a). The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: Implications for neurotoxicity. Psychopharmacology (Berl.) 197, 263-278.
26. Goni-Allo, B., Puerta, E., Mathuna, B. O., Hervias, I., Lasheras, B., de la Torre, R., and Aguirre, N. (2008b). On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats. Neuropharmacology 54, 885-900.
27. Gordon, C. J., Watkinson, W. P., O'Callaghan, J. P., and Miller, D. B. (1991). Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol. Biochem. Behav. 38, 339-344.
28. Jones, D. C., Duvauchelle, C., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R., and Monks, T. J. (2005). Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 313, 422-431.
29. Kadowaki, M., Ootani, E., Sugihara, N., and Furuno, K. (2005). Inhibitory effects of catechin gallates on o-methyltranslation of protocatechuic acid in rat liver cytosolic preparations and cultured hepatocytes. Biol. Pharm. Bull. 28, 1509-1513.
30. Lim, H. K., Zeng, S., Chei, D. M., and Foltz, R. L. (1992). Comparative investigation of disposition of 3,4-(methylenedioxy)methamphetamine (MDMA) in the rat and the mouse by a capillary gas chromatography-mass spectrometry assay based on perfluorotributylamine-enhanced ammonia positive ion chemical ionization. J. Pharm. Biomed. Anal. 10, 657-665.
31. Miller, R. T., Lau, S. S., and Monks, T. J. (1996). Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague- Dawley rats. Chem. Res. Toxicol. 9, 457-465.
32. Miller, R. T., Lau, S. S., and Monks, T. J. (1997). 2,5-Bis-(glutathion- S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4- methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur. J. Pharmacol. 323, 173-180.
33. Mills, E.M., Rusyniak, D. E., and Sprague, J. E. (2004). The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J. Mol. Med. (Berl.) 82, 787-799.
34. Mueller, M., Yuan, J., Maldonado Adrian, C., McCann, U. D., and Ricaurte, G.A. (2011). Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neurotoxicity: Implications for mechanisms of neurotoxicity. Synapse 65, 983-990.
35. O'Callaghan, J. P., and Miller, D. B. (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741-751.
36. O'Hearn, E., Battaglia, G., De Souza, E. B., Kuhar, M. J., and Molliver, M. E. (1988). Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J. Neurosci. 8, 2788-2803.
37. Perfetti, X., O'Mathuna, B., Pizarro, N., Cuyas, E., Khymenets, O., Almeida, B., Pellegrini, M., Pichini, S., Lau, S. S., Monks, T. J., et al. (2009). Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab. Dispos. 37, 1448-1455.
38. Ribeiro, M. O., Lebrun, F. L., Christoffolete, M. A., Branco, M., Crescenzi, A., Carvalho, S. D., Negrao, N., and Bianco, A. C. (2000). Evidence of UCP1- independent regulation of norepinephrine-induced thermogenesis in brown fat. Am. J. Physiol. Endocrinol. Metab. 279, E314-E322.
39. Romanovsky, A. A., Sugimoto, N., Simons, C. T., and Hunter, W. S. (2003). The organum vasculosum laminae terminalis in immune-to-brain febrigenic signaling: A reappraisal of lesion experiments. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R420-R428.
40. Sanchez, V., Camarero, J., O'Shea, E., Green, A. R., and Colado, M. I. (2003). Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology 44, 449-461.
41. Schilt, T., Koeter, M. W., de Win, M. M., Zinkstok, J. R., van Amelsvoort, T. A., Schmand, B., and den Brink, W. (2009). The effect of Ecstasy on memory is moderated by a functional polymorphism in the cathechol-Omethyltransferase (COMT) gene. Eur. Neuropsychopharmacol. 19, 116-124.
42. Shioda, K., Nisijima, K., Yoshino, T., Kuboshima, K., Iwamura, T., Yui, K., and Kato, S. (2008). Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology 29, 1030-1036.
43. Slikker, W., Jr, Ali, S. F., Scallet, A. C., Frith, C. H., Newport, G. D., and Bailey, J. R. (1988). Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol. Appl. Pharmacol. 94, 448-457.
44. Sprague, J. E., Moze, P., Caden, D., Rusyniak, D. E., Holmes, C., Goldstein, D.S., and Mills, E. M. (2005). Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model. Crit. Care Med. 33, 1311-1316.
45. Stone, D.M., Hanson, G. R., and Gibb, J. W. (1987a). Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26, 1657-1661.
46. Stone, D. M., Johnson, M., Hanson, G. R., and Gibb, J. W. (1987b). A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur. J. Pharmacol. 134, 245-248.
47. Tammimaki, A. E., and Mannisto, P. T. (2010). Are genetic variants of COMT associated with addiction? Pharmacogenet. Genomics 20, 717-741.
48. Tunbridge, E.M. (2010). The catechol-O-methyltransferase gene: Its regulation and polymorphisms. Int. Rev. Neurobiol. 95, 7-27.
49. Wyeth, R. P., Mills, E. M., Ullman, A., Kenaston, M. A., Burwell, J., and Sprague, J. E. (2009). The hyperthermia mediated by 3,4- methylenedioxymethamphetamine (MDMA, Ecstasy) is sensitive to sex differences. Toxicol. Appl. Pharmacol. 235, 33-38.